Journal of Antimicrobial Chemotherapy (2001) 48, 15-22
© 2001 The British Society for Antimicrobial Chemotherapy
The effect of pharmacokinetics on the bactericidal activity of ciprofloxacin and sparfloxacin against Streptococcus pneumoniae and the emergence of resistance
Chemotherapy Research Unit, Department of Life Sciences, University of East London, Romford Road, London E15 4LZ, UK
The pharmacokinetics of ciprofloxacin and sparfloxacin were simulated in vitro and the effects of pharmacodynamic parameters on bactericidal activity and the emergence of quinolone resistance were examined for Streptococcus pneumoniae. Simulated serum concentrations of ciprofloxacin 500 mg bd were more rapidly bactericidal than sparfloxacin 200 mg bd, despite lower values for the key pharmacodynamic parameters (AUC/MIC and Cmax/MIC). This was possibly related to the slower oral absorption of sparfloxacin, which delayed achievement of the MIC compared with ciprofloxacin. In addition, sparfloxacin was shown to have similar bactericidal activity to ciprofloxacin when tested at the same concentrations, despite its four-fold better potency in MIC terms. The emergence of resistance following exposure to ciprofloxacin appeared to be dependent on the Cmax/MIC ratio and the AUC above the MIC, but not the AUC/MIC ratio. Resistance (at least four-fold increase in MIC) developed when the Cmax/MIC ratio was less than four or the AUC above the MIC was less than 10, and the resulting cultures regrew fully. In contrast, pneumococci with a two- to four-fold increase in sparfloxacin MIC were selected in the presence of serum concentrations of sparfloxacin despite a Cmax/MIC ratio higher than 12, but these isolates remained clinically susceptible by breakpoint MIC and their growth was inhibited by repeated dosage of sparfloxacin. Nevertheless, the selection of pneumococci with reduced susceptibility, and the possibility of further mutation to highly resistant strains supports the use of quinolones that rapidly eradicate pneumococci at conventional doses and achieve concentrations, in both serum and tissues, which exceed at least 4 x MIC.
* Corresponding author. Tel: +44-20-8223-3000, ext. 4074; Fax: +44-20-8223-4959; E-mail: d.i.edwards{at}uel.ac.uk
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  D. Croisier, M. Etienne, E. Bergoin, P.-E. Charles, C. Lequeu, L. Piroth, H. Portier, and P. Chavanet Mutant Selection Window in Levofloxacin and Moxifloxacin Treatments of Experimental Pneumococcal Pneumonia in a Rabbit Model of Human Therapy Antimicrob. Agents Chemother., May 1, 2004; 48(5): 1699 - 1707. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. H. Zinner, I. Yu. Lubenko, D. Gilbert, K. Simmons, X. Zhao, K. Drlica, and A. A. Firsov Emergence of resistant Streptococcus pneumoniae in an in vitro dynamic model that simulates moxifloxacin concentrations inside and outside the mutant selection window: related changes in susceptibility, resistance frequency and bacterial killing J. Antimicrob. Chemother., October 1, 2003; 52(4): 616 - 622. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. A. Firsov, S. N. Vostrov, I. Y. Lubenko, K. Drlica, Y. A. Portnoy, and S. H. Zinner In Vitro Pharmacodynamic Evaluation of the Mutant Selection Window Hypothesis Using Four Fluoroquinolones against Staphylococcus aureus Antimicrob. Agents Chemother., May 1, 2003; 47(5): 1604 - 1613. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. P. MacGowan, C. A. Rogers, H. A. Holt, and K. E. Bowker Activities of Moxifloxacin against, and Emergence of Resistance in, Streptococcus pneumoniae and Pseudomonas aeruginosa in an In Vitro Pharmacokinetic Model Antimicrob. Agents Chemother., March 1, 2003; 47(3): 1088 - 1095. [Abstract] [Full Text] [PDF]
|
|